| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
In patients with chronic kidney disease(CKD) and acute kidney injury(AKI), the uremic toxins might promote renal damages and anemia by cytotoxicities and repression of the expression of renal uremic toxin transporter SLCO4C1and hematopoietic hormone erythropoietin (Epo) produce in the klidney. We explored the new drugs for kidney disease by screening compounds library with Epo producing cells and kidney derived cells. We identified newly synthesized indole compounds and those compounds improved the renal functions and the kidney pathological scores in two mice AKI models, ischemic repercussion injury-model and cisplatin nephropathy. The indole compounds increased the intra cellular ATP content in kidney derived culture cells. The indole derivatives could be the new therapeutic agents for kidney diseases.
|
